"Castle Biosciences Inc. today announced results of a 217-patient study demonstrating that its gene expression profile (GEP) test, DecisionDx-Melanoma, identified primary cutaneous (skin) melanoma tumors that were sentinel lymph node biopsy negative but were at high risk of metastasis. The GEP test also identified tumors that were unlikely to become metastatic, independent of nodal status. The data are being reviewed today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in the Melanoma/Skin Cancers Poster Highlights Session by David H. Lawson, M.D., Professor of Hematology and Medical Oncology, Winship Cancer Institute, Emory University."


Editor's note: More and more, doctors are using molecular testing methods to make diagnoses and guide treatment decisions. Now, molecular testing can help determine whether a melanoma tumor is likely to metastasize (spread to other parts of the body). A procedure called sentinel lymph node biopsy is commonly used to measure the severity of a melanoma diagnosis; a "negative" sentinel node biopsy indicates low risk of metastasis. But some patients with negative sentinel node biopsies still go on to experience metastasis. A new molecular test called DecisionDx-Melanoma can identify cutaneous melanoma tumors that are at risk of metastasizing, regardless of sentinel node biopsy results. The test analyzes the activity of 31 genes in a tumor to determine risk of metastasis.